Evidence map›Paper›PMID 27716788›Full record

ArticlePLoS genetics2016

Vimar Is a Novel Regulator of Mitochondrial Fission through Miro.

Lianggong Ding, Ye Lei, Yanping Han, Yuhong Li, Xunming Ji, Lei Liu

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Miro: A molecular switch at the center of mitochondrial regulation.Protein science : a publication of the Protein Society · 2020
    Review
  14. Article
  15. Article
  16. Article
  17. The Emerging Role ofFrontiers in neurology · 2020
    Review
  18. DISC1 Regulates Mitochondrial Trafficking in a Miro1-GTP-Dependent Manner.Frontiers in cell and developmental biology · 2020
    Article
  19. Frontiers in neurology · 2020
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Lianggong DingState Key Laboratory of Membrane Biology, School of Life Sciences, Peking University, Beijing, China.
Ye LeiState Key Laboratory of Membrane Biology, School of Life Sciences, Peking University, Beijing, China.ORCID http://orcid.org/0000-0002-7432-4038
Yanping HanAging and Disease lab of Xuanwu Hospital and Beijing Institute for Brain Disorders, Capital Medical University, Youanmen, Beijing, China.
Yuhong LiAging and Disease lab of Xuanwu Hospital and Beijing Institute for Brain Disorders, Capital Medical University, Youanmen, Beijing, China.
Xunming JiAging and Disease lab of Xuanwu Hospital and Beijing Institute for Brain Disorders, Capital Medical University, Youanmen, Beijing, China.
Lei LiuAging and Disease lab of Xuanwu Hospital and Beijing Institute for Brain Disorders, Capital Medical University, Youanmen, Beijing, China.
Capital Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As fundamental processes in mitochondrial dynamics, mitochondrial fusion, fission and transport are regulated by several core components, including Miro. As an atypical Rho-like small GTPase with high molecular mass, the exchange of GDP/GTP in Miro may require assistance from a guanine nucleotide exchange factor (GEF). However, the GEF for Miro has not been identified. While studying mitochondrial morphology in Drosophila, we incidentally observed that the loss of vimar, a gene encoding an atypical GEF, enhanced mitochondrial fission under normal physiological conditions. Because Vimar could co-immunoprecipitate with Miro in vitro, we speculated that Vimar might be the GEF of Miro. In support of this hypothesis, a loss-of-function (LOF) vimar mutant rescued mitochondrial enlargement induced by a gain-of-function (GOF) Miro transgene; whereas a GOF vimar transgene enhanced Miro function. In addition, vimar lost its effect under the expression of a constitutively GTP-bound or GDP-bound Miro mutant background. These results indicate a genetic dependence of vimar on Miro. Moreover, we found that mitochondrial fission played a functional role in high-calcium induced necrosis, and a LOF vimar mutant rescued the mitochondrial fission defect and cell death. This result can also be explained by vimar's function through Miro, because Miro's effect on mitochondrial morphology is altered upon binding with calcium. In addition, a PINK1 mutant, which induced mitochondrial enlargement and had been considered as a Drosophila model of Parkinson's disease (PD), caused fly muscle defects, and the loss of vimar could rescue these defects. Furthermore, we found that the mammalian homolog of Vimar, RAP1GDS1, played a similar role in regulating mitochondrial morphology, suggesting a functional conservation of this GEF member. The Miro/Vimar complex may be a promising drug target for diseases in which mitochondrial fission and fusion are dysfunctional.

Indexed as

AnimalsArmadillo Domain ProteinsCalciumChlorocebus aethiopsCOS CellsDrosophila melanogasterDrosophila ProteinsGuanine Nucleotide Exchange FactorsHumansMitochondriaMitochondrial DynamicsNecrosisParkinson Diseaserho GTP-Binding ProteinsRNA InterferenceArmadillo Domain ProteinsCalciumDrosophila ProteinsGuanine Nucleotide Exchange FactorsMiro protein, DrosophilaRAP1GDS1 protein, humanrho GTP-Binding Proteinsvimar protein, Drosophila

Identifiers

PMID27716788
PMCPMC5065127
OpenAlexW2529587274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.